<unk> (oral) is a {{{drugClass}}} that is FDA approved for the treatment of partial onset seizures in patients one month of age and older with epilepsy, myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy, primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.   Common adverse reactions include somnolence, asthenia, infection, dizziness, fatigue, aggression, nasal congestion, decreased appetite, and irritability.
Levetiracetam 
Oxiracetam
Piracetam
Mesuximide
Methsuximide
Brivaracetam
Lamotrigine
Ethosuximide